Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fuerea A, Ribrag V, Gazzah A, Armand JP, Amellal N, Angevin E, Noel N, Boutros C, Mateus C, Robert C, Soria JC, Marabelle A, Lambotte O. Michot JM, et al. Among authors: angevin e. Eur J Cancer. 2016 Feb;54:139-148. doi: 10.1016/j.ejca.2015.11.016. Epub 2016 Jan 5. Eur J Cancer. 2016. PMID: 26765102 Review.
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.
Camidge DR, Barlesi F, Goldman JW, Morgensztern D, Heist R, Vokes E, Spira A, Angevin E, Su WC, Hong DS, Strickler JH, Motwani M, Dunbar M, Parikh A, Noon E, Blot V, Wu J, Kelly K. Camidge DR, et al. Among authors: angevin e. J Clin Oncol. 2023 Feb 10;41(5):1105-1115. doi: 10.1200/JCO.22.00739. Epub 2022 Oct 26. J Clin Oncol. 2023. PMID: 36288547 Free PMC article. Clinical Trial.
Dendritic cell-based immunotherapy of cancer.
Zitvogel L, Angevin E, Tursz T. Zitvogel L, et al. Among authors: angevin e. Ann Oncol. 2000;11 Suppl 3:199-205. doi: 10.1093/annonc/11.suppl_3.199. Ann Oncol. 2000. PMID: 11079142 Free article. Review. No abstract available.
Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma.
Camidge DR, Morgensztern D, Heist RS, Barve M, Vokes E, Goldman JW, Hong DS, Bauer TM, Strickler JH, Angevin E, Motwani M, Parikh A, Sun Z, Bach BA, Wu J, Komarnitsky PB, Kelly K. Camidge DR, et al. Among authors: angevin e. Clin Cancer Res. 2021 Nov 1;27(21):5781-5792. doi: 10.1158/1078-0432.CCR-21-0765. Epub 2021 Aug 23. Clin Cancer Res. 2021. PMID: 34426443 Free PMC article. Clinical Trial.
The search for therapeutic targets in lung cancer: Preclinical and human studies of carcinoembryonic antigen-related cell adhesion molecule 5 expression and its associated molecular landscape.
Lefebvre AM, Adam J, Nicolazzi C, Larois C, Attenot F, Falda-Buscaiot F, Dib C, Masson N, Ternès N, Bauchet AL, Demers B, Chadjaa M, Sidhu S, Combeau C, Soria JC, Scoazec JY, Naimi S, Angevin E, Chiron M, Henry C. Lefebvre AM, et al. Among authors: angevin e. Lung Cancer. 2023 Oct;184:107356. doi: 10.1016/j.lungcan.2023.107356. Epub 2023 Aug 26. Lung Cancer. 2023. PMID: 37660479 Free article.
103 results